These results suggested that BRD7 could inhibit the exhaustion of CD8+ T cells, enhance their killing function against tumor cells, and the addition of the PD-L1 antibody further inhibit this phenomenon, and could reverse the exhaustion of CD8+ T cells caused by downregulation of BRD7 expression. Here, CD8A is linked to neoplasm.